Incidence
of Cancer
Each year, cancer claims millions of lives. This year alone, estimates
indicate that cancer will claim 7.2 million people worldwide.
In the US, cancer will claim an estimated 550,000 people and consequently
account for approximately 25% of all deaths that will occur in
the US this year. Statistics further predict that 2.3 million
new cases of cancer were diagnosed in the US in 2005. Even more
daunting, in the US alone medical data suggests that 1 in 2 men
will get cancer, as will 1 woman in 3, over their respective lifetimes.
Incidence
of Ophthalmic Disease
In the United States, 35 million people experience Age-related
Macular Degeneration (AMD), Diabetic Retinopathy, Glaucoma, and
Cataracts. These conditions can lead to loss of independence and
significantly reduce quality of life.
Today,
9 million people in the United States over the age of 40 have
intermediate-to-advanced stage vision loss caused by AMD. One
out of every two people over age 85 have AMD, and the population
of individuals over age 85 is the most rapidly growing segment
of the population.
Currently,
more than four million Americans over the age of 40 have diabetic
retinopathy, or about 1 in 12.
By
2020, our nation will likely have more than 50 million Americans
with significant vision loss or blindness.
With
the incidence of disease in both markets so high, the amount of
money spent on medical care, pharmaceuticals and research reaches
into the billions of dollars each year. The success of CIF as
a medical treatment in either market would insure Biomega's commercial
and financial success.
Biomega Laboratories has licensed the rights to
the CIF technology from NYUSM in exchange for conducting CIF research
at NYUSM, paying patent costs related to this technology, and
paying various milestone fees to the University. It addition,
NYUSM and key NYUSM Professors have equity positions in the Company.
The Company filed a "Composition of Matter" US Patent
Application and a PCT Patent Application covering the structure
of CIF in 4Q2005. These two recent applications add to the Company's
original US Patent Application covering the use of a factor as
an anti-metastatic and anti-angiogenic agent. These applications
will eventually form the base for a contemplated umbrella of patents
covering all aspects of CIF's activity.
The company has a number of clear advantages that
strongly support its future growth.
- NYU School of Medicine Affiliation.
- Management
- Scientific Advisory Board
- Clearly targeted scientific experiments
and business milestones.
- Clearly identified products.
- Potential to create a therapeutic platform
that can lead to a number of small molecular NCE's (New Chemical
Entities), again increasing IP value.
The
Company plans to pursue a multiple product development plan at
least through the preclinical phase of CIF development leading
to the filing of an IND.
It
will look at both FDA Fast Track opportunities in ophthalmics
and oncology.
Contemplated
indications in the oncology area are glioma, renal cell carcinoma
and melanoma, the disease that Biomega is most familiar with.
In
the ophthalmic area proliferative vitreoretinopathy and adult
onset wet macular degeneration are being considered.
Three
primary entities currently support the work on CIF™: Biomega Laboratories,
the NYU School of Medicine and the School's Department of Dermatology.
In addition, Dr. Lipkin has applied for and received various government
and foundation grants to support his work to date.
Biomega
will be responsible for providing funding to move CIF™ to the
next level of research, and the funds raised by the company will
support those efforts for the next two years.
CIF is the first naturally occurring peptide
discovered that regulates the growth of cells in the body. And
because of this, CIF and the future developed daughter molecules
of CIF have the potential to effectively treat many diseases,
but most notably cancer.
Biomega offers an opportunity for philanthropic
investors that wish to give back to society; to do good in the
World while they make a profit on their investment.
Biomega was founded by just such people.
We look forward to you joining us.
For a copy of the Company's Executive Summary
and/or its business plan please contact
Richard
D. Glaser, Ph.D.
CEO and President
To
learn more, please contact:
Biomega Laboratories, Inc.
In
Care of: Richard D. Glaser, Ph.D.
NYC Phone:
(212) 307-4386 | CT Phone: (203)
838-6918 | Mobile
Phone: (917) 975-8400
Email: rdglaser@earthlink.net.
